These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
448 related articles for article (PubMed ID: 16585204)
1. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Nawrocki ST; Carew JS; Pino MS; Highshaw RA; Andtbacka RH; Dunner K; Pal A; Bornmann WG; Chiao PJ; Huang P; Xiong H; Abbruzzese JL; McConkey DJ Cancer Res; 2006 Apr; 66(7):3773-81. PubMed ID: 16585204 [TBL] [Abstract][Full Text] [Related]
2. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Pei XY; Dai Y; Grant S Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093 [TBL] [Abstract][Full Text] [Related]
3. Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Nawrocki ST; Carew JS; Pino MS; Highshaw RA; Dunner K; Huang P; Abbruzzese JL; McConkey DJ Cancer Res; 2005 Dec; 65(24):11658-66. PubMed ID: 16357177 [TBL] [Abstract][Full Text] [Related]
4. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma. Heider U; von Metzler I; Kaiser M; Rosche M; Sterz J; Rötzer S; Rademacher J; Jakob C; Fleissner C; Kuckelkorn U; Kloetzel PM; Sezer O Eur J Haematol; 2008 Feb; 80(2):133-42. PubMed ID: 18005386 [TBL] [Abstract][Full Text] [Related]
5. Proteasome inhibition sensitizes non-small cell lung cancer to histone deacetylase inhibitor-induced apoptosis through the generation of reactive oxygen species. Denlinger CE; Rundall BK; Jones DR J Thorac Cardiovasc Surg; 2004 Nov; 128(5):740-8. PubMed ID: 15514602 [TBL] [Abstract][Full Text] [Related]
6. Vorinostat enhances the antimyeloma effects of melphalan and bortezomib. Campbell RA; Sanchez E; Steinberg J; Shalitin D; Li ZW; Chen H; Berenson JR Eur J Haematol; 2010 Mar; 84(3):201-11. PubMed ID: 19929977 [TBL] [Abstract][Full Text] [Related]
7. SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib. Emanuele S; Lauricella M; Carlisi D; Vassallo B; D'Anneo A; Di Fazio P; Vento R; Tesoriere G Apoptosis; 2007 Jul; 12(7):1327-38. PubMed ID: 17351739 [TBL] [Abstract][Full Text] [Related]
8. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells. Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun SY Cancer Res; 2007 May; 67(10):4981-8. PubMed ID: 17510429 [TBL] [Abstract][Full Text] [Related]
9. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma. Heider U; Rademacher J; Lamottke B; Mieth M; Moebs M; von Metzler I; Assaf C; Sezer O Eur J Haematol; 2009 Jun; 82(6):440-9. PubMed ID: 19220424 [TBL] [Abstract][Full Text] [Related]
10. Anti-tumor activity of the proteasome inhibitor bortezomib in gastric cancer. Nakata W; Hayakawa Y; Nakagawa H; Sakamoto K; Kinoshita H; Takahashi R; Hirata Y; Maeda S; Koike K Int J Oncol; 2011 Dec; 39(6):1529-36. PubMed ID: 21785822 [TBL] [Abstract][Full Text] [Related]
11. The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis. Zhang QL; Wang L; Zhang YW; Jiang XX; Yang F; Wu WL; Janin A; Chen Z; Shen ZX; Chen SJ; Zhao WL Leukemia; 2009 Aug; 23(8):1507-14. PubMed ID: 19282831 [TBL] [Abstract][Full Text] [Related]
12. Effect of noncompetitive proteasome inhibition on bortezomib resistance. Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154 [TBL] [Abstract][Full Text] [Related]
13. Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2,5-dimethyl-celecoxib. Kardosh A; Golden EB; Pyrko P; Uddin J; Hofman FM; Chen TC; Louie SG; Petasis NA; Schönthal AH Cancer Res; 2008 Feb; 68(3):843-51. PubMed ID: 18245486 [TBL] [Abstract][Full Text] [Related]
14. Bortezomib (Velcade) induces p27Kip1 expression through S-phase kinase protein 2 degradation in colorectal cancer. Uddin S; Ahmed M; Bavi P; El-Sayed R; Al-Sanea N; AbdulJabbar A; Ashari LH; Alhomoud S; Al-Dayel F; Hussain AR; Al-Kuraya KS Cancer Res; 2008 May; 68(9):3379-88. PubMed ID: 18451165 [TBL] [Abstract][Full Text] [Related]
15. Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma. Paoluzzi L; Scotto L; Marchi E; Zain J; Seshan VE; O'Connor OA Clin Cancer Res; 2010 Jan; 16(2):554-65. PubMed ID: 20068080 [TBL] [Abstract][Full Text] [Related]
17. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells. Chen KF; Yeh PY; Yeh KH; Lu YS; Huang SY; Cheng AL Cancer Res; 2008 Aug; 68(16):6698-707. PubMed ID: 18701494 [TBL] [Abstract][Full Text] [Related]
18. The proteasome inhibitor bortezomib induces apoptosis in human retinoblastoma cell lines in vitro. Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMillin D; Miller JW; Mitsiades N Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4706-19. PubMed ID: 17898295 [TBL] [Abstract][Full Text] [Related]
19. Interactions between bortezomib and romidepsin and belinostat in chronic lymphocytic leukemia cells. Dai Y; Chen S; Kramer LB; Funk VL; Dent P; Grant S Clin Cancer Res; 2008 Jan; 14(2):549-58. PubMed ID: 18223231 [TBL] [Abstract][Full Text] [Related]
20. Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia. Pahler JC; Ruiz S; Niemer I; Calvert LR; Andreeff M; Keating M; Faderl S; McConkey DJ Clin Cancer Res; 2003 Oct; 9(12):4570-7. PubMed ID: 14555532 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]